Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Administration
10 evidence topics · 11 sources
Orally disintegrating tablet
Required 8-hour monitoring and end-of-session checklist in the Phase 3 trials
End-of-session checklist content and development
Session length in Voyage: topline announcement
Session length in Voyage: congress poster
Session length in Panorama and across the Phase 3 trials
Dosing session monitors and on-call clinician in the Phase 3 trials
Phase 2b dosing session procedures and 12-hour monitoring
“On the dosing day, participants received a single oral dose of MM120 or placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participant dosing sessions were conducted individually in a private aesthetically pleasant room.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Continuous monitoring was required for a minimum of 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 2b: time to meet criteria to end the session at 100 µg
“In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote